BioCryst Reports Fourth Quarter and Full Year 2016 Financial Results


BioCryst Pharmaceuticals, Inc. announced today financial results for the fourth quarter and full year ended December 31, 2016. In a separate press release issued earlier today, BioCryst announced positive results from an interim analysis of its APeX-1 clinical trial of BCX7353 for the treatment of HAE attacks.



from Biotech News